[1] 江堤,扬光,罗万蓉,等.乙型肝炎病毒表面抗原阳性肺结核患者抗结核治疗肝功损害研究.现代预防医学,2010,37（17）：3347-3356.
[2] 赵一红,张振显.抗结核药物对乙型肝炎病毒标志物阳性肺结核患者肝功能影响及处理.医药论坛杂志,2010,31（18）：155-156.
[3] Stoop JN,Van Der Molen RG,Kuipers EJ,et al Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B.Virology,2007,361（1）:141-148.
[4] 中华医学会.临床诊疗指南结核病分册.北京：人民卫生出版社,2005：829.
[5] 梁晓峰,陈园生,王晓军,等.中国3岁以上人群乙型肝炎血清流行病学研究.中华流行病学杂志,2005,26（9）：655-658.
[6] Hussain Z,Kar P,Husain SA. Antituberculosis drug-induced
hepatitis：risk factors,prevention and management. Indian J Exp Biol,2003,41：1226-1232.
[7] Tostmann A, Boeree MJ,Peters WH,et al. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinarnide toxicity. Int J Antimicrob Agents,2008,31：577-580.
[8] 刘建军,刘传宝.抗结核药物对乙型肝炎病毒携带者合并肺结核患者肝功能的影响.药物与临床,2009,16（5）：43-44.
[9] Kim JW,Park SH,louie SG. Telbivudine：a novel nucleoside analog for chronic hepatitis B.Ann Pharmacother,2006,40:472-478.
[10] Ohno M ,Yamaguchi I,Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tubere Lung Dis,2000,4:256-261.
[11] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）.实用肝脏病杂志,2011,4（2）：81-89.
[12] Parthasarathy R,Sarma GR,Janardhanam B,et al.Hepatic toxicity in South Indian patients during treatment of tuberculosis with short course regimens containing isoniazid,rifampicin and pyrazinamide.Tuberculosis,1986,67（2）:99.
[13] Turktas H,Unsal M,Tulek N,et al.Hepatotoxicity of antituberculosis therapy（rifampicin,isoniazid and pyrazinamide）orviral hepatitis. Tuber Lung Dis,1994,75（1）:58.
[14] 夏愔愔,詹思延.国内抗结核药物不良反应发生率的综合分析.中华结核和呼吸杂志,2007,30：419-423. |
